Cargando…
Aberrantly hypermethylated ARID1B is a novel biomarker and potential therapeutic target of colon adenocarcinoma
Background and Objective: Understanding the tumor microenvironment (TME) and immune cell infiltration (ICI) may help guide immunotherapy efforts for colon cancer (COAD). However, whether ARID1B is truly regulated by hypermethylation or linked to immune infiltration remains unknown. The current work...
Autores principales: | Baldi, Salem, He, Yun, Ivanov, Igor, Khamgan, Hassan, Safi, Mohammed, Alradhi, Mohammed, Shopit, Abdullah, Al-Danakh, Abdullah, Al-Nusaif, Murad, Gao, Yaping, Tian, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614077/ https://www.ncbi.nlm.nih.gov/pubmed/36313455 http://dx.doi.org/10.3389/fgene.2022.914354 |
Ejemplares similares
-
ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression
por: Baldi, Salem, et al.
Publicado: (2022) -
Downregulated ARID1A by miR-185 Is Associated With Poor Prognosis and Adverse Outcomes in Colon Adenocarcinoma
por: Baldi, Salem, et al.
Publicado: (2021) -
Surgery improves survival in bladder signet-ring cell carcinoma-a population-based study
por: Alradhi, Mohammed, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study
por: Al-Danakh, Abdullah, et al.
Publicado: (2022) -
Molecular genetic and clinical characteristic analysis of primary signet ring cell carcinoma of urinary bladder identified by a novel OR2L5 mutation
por: Alradhi, Mohammed, et al.
Publicado: (2022)